RESECTABLE PANCREATIC ADENOCARCINOMA
Clinical trials for RESECTABLE PANCREATIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RESECTABLE PANCREATIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RESECTABLE PANCREATIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted drug trial aims to keep pancreatic cancer from coming back
Disease control Recruiting nowThis study is testing if adding the drug olaparib after surgery and chemotherapy can help prevent pancreatic cancer from returning. It is for patients whose cancer has been surgically removed and who have specific genetic mutations (BRCA1, BRCA2, or PALB2). Participants will take…
Matched conditions: RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
Triple attack on pancreatic cancer before surgery aims to extend lives
Disease control Recruiting nowThis study is testing a new three-part treatment for patients with pancreatic cancer that can be surgically removed. Before surgery, patients receive a combination of chemotherapy, immunotherapy, and targeted radiation. The goal is to see if this intensive approach helps control …
Matched conditions: RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Amsterdam UMC, location VUmc • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Scientists search for genetic clues behind Cancer-Related weight loss
Knowledge-focused Recruiting nowThis study aims to understand why pancreatic cancer patients experience severe weight loss and muscle wasting (called cachexia). Researchers will examine tumor tissue from 100 patients undergoing surgery to identify genetic differences that might explain this condition. The study…
Matched conditions: RESECTABLE PANCREATIC ADENOCARCINOMA
Sponsor: University of Oklahoma • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:38 UTC